T. W. Siegel

发表

Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.

B. Mylari, E. R. Larson, T. A. Beyer, 1991, Journal of medicinal chemistry.

A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.

B. Mylari, T. A. Beyer, T. W. Siegel, 1991, Journal of medicinal chemistry.

Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.

C. Lipinski, T. A. Beyer, C. Aldinger, 1992, Journal of medicinal chemistry.

An enzymatic fluorometric assay for fructose.

J. Williamson, T. W. Siegel, S. R. Smith, 2000, Analytical biochemistry.

Purification and properties of the human placental insulin receptor.

O. Rosen, C. Rubin, T. W. Siegel, 1981, The Journal of biological chemistry.

The role of polyols in cerebral cell volume regulation in hypernatremic and hyponatremic states.

E. Hammer, H. Trachtman, T. W. Siegel, 1991, Life sciences.

Small molecule somatostatin receptor subtype-2 antagonists.

D. Pelletier, F. Dicapua, B. Hay, 2001, Bioorganic & medicinal chemistry letters.

Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives.

B. Mylari, T. A. Beyer, W. Zembrowski, 1992, Journal of medicinal chemistry.

Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.

B. Mylari, T. A. Beyer, W. Zembrowski, 1992, Journal of medicinal chemistry.

Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids

T. A. Beyer, T. W. Siegel, R. Sarges, 1992 .

Genetic control of insulin receptors.

C. Rubin, T. W. Siegel, A. Goldfeld, 1981, Proceedings of the National Academy of Sciences of the United States of America.